X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GLENMARK PHARMA VENUS REMEDIES/
GLENMARK PHARMA
 
P/E (TTM) x -693.1 12.2 - View Chart
P/BV x 0.2 3.2 6.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   GLENMARK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
GLENMARK PHARMA
Mar-17
VENUS REMEDIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs218993 22.0%   
Low Rs82729 11.3%   
Sales per share (Unadj.) Rs365.6325.5 112.3%  
Earnings per share (Unadj.) Rs1.539.3 3.8%  
Cash flow per share (Unadj.) Rs37.948.7 77.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs382.5159.2 240.3%  
Shares outstanding (eoy) m11.44282.17 4.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.42.6 15.5%   
Avg P/E ratio x101.021.9 460.7%  
P/CF ratio (eoy) x4.017.7 22.4%  
Price / Book Value ratio x0.45.4 7.3%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m1,717242,991 0.7%   
No. of employees `0001.013.0 7.9%   
Total wages/salary Rs m32416,408 2.0%   
Avg. sales/employee Rs Th4,100.77,083.9 57.9%   
Avg. wages/employee Rs Th318.01,265.4 25.1%   
Avg. net profit/employee Rs Th16.7855.1 1.9%   
INCOME DATA
Net Sales Rs m4,18391,857 4.6%  
Other income Rs m20374 5.4%   
Total revenues Rs m4,20392,230 4.6%   
Gross profit Rs m81220,367 4.0%  
Depreciation Rs m4172,644 15.8%   
Interest Rs m3802,373 16.0%   
Profit before tax Rs m3515,724 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m183,827 0.5%   
Profit after tax Rs m1711,088 0.2%  
Gross profit margin %19.422.2 87.5%  
Effective tax rate %51.624.3 211.9%   
Net profit margin %0.412.1 3.4%  
BALANCE SHEET DATA
Current assets Rs m2,77168,746 4.0%   
Current liabilities Rs m1,93127,027 7.1%   
Net working cap to sales %20.145.4 44.2%  
Current ratio x1.42.5 56.4%  
Inventory Days Days12585 147.1%  
Debtors Days Days5496 56.3%  
Net fixed assets Rs m5,32824,132 22.1%   
Share capital Rs m114282 40.5%   
"Free" reserves Rs m4,17744,643 9.4%   
Net worth Rs m4,37644,925 9.7%   
Long term debt Rs m1,91145,363 4.2%   
Total assets Rs m8,428117,639 7.2%  
Interest coverage x1.17.6 14.3%   
Debt to equity ratio x0.41.0 43.2%  
Sales to assets ratio x0.50.8 63.6%   
Return on assets %4.711.4 41.1%  
Return on equity %0.424.7 1.6%  
Return on capital %6.619.1 34.5%  
Exports to sales %00-   
Imports to sales %20.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m858NA-   
Fx inflow Rs m056,152 0.0%   
Fx outflow Rs m8588,084 10.6%   
Net fx Rs m-85848,068 -1.8%   
CASH FLOW
From Operations Rs m4696,574 7.1%  
From Investments Rs m29-7,124 -0.4%  
From Financial Activity Rs m-4645,432 -8.5%  
Net Cashflow Rs m351,992 1.7%  

Share Holding

Indian Promoters % 32.9 48.3 68.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.6%  
FIIs % 0.6 34.4 1.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.5 632.4%  
Shareholders   20,121 56,727 35.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS